Efficacy and clinical tolerance of a new combination of trimethoprim with sulphonamide. A post-marketing and a literature survey.
To obtain a direct clinical evaluation of a new sulpha-trimethoprim combination product (Kelfiprim) from general practitioners or specialist practitioners, an extensive post-marketing survey has been organized in Brazil involving 1,177 doctors and 5,885 patients. These experienced different infections susceptible to oral antimicrobial chemotherapy with a sulpha-trimethoprim combination. The results indicated that the product was very effective (91.2% cure rate) and well tolerated (4% incidence of side-effects). Side-effects were usually mild and transient. No life-threatening adverse reactions were observed. The results obtained support those already published in clinical trials involving 1,119 patients.
D001424:Bacterial Infections / Q000188:drug therapy*; D001938:Brazil; D004338:Drug Combinations / Q000627:therapeutic use / Q000633:toxicity; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D006801:Humans; D011358:Product Surveillance, Postmarketing; D013415:Sulfalene / Q000627:therapeutic use* / Q000633:toxicity; D013424:Sulfanilamides / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use* / Q000633:toxicity
D004338:Drug Combinations; D013424:Sulfanilamides; C026911:kelfiprim; D014295:Trimethoprim; D013415:Sulfalene